FMFlorian Malard

Florian Malard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Florian Malard has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SCKAnalyzer: A Web Tool for Single-Cycle Kinetics Analysis and Simulation

    by Florian Malard, Jean-Michel Blanc, Eric Roubin, Thomas Schäfer, Carmelo Di Primo

    Surface plasmon resonance (SPR) and biolayer interferometry (BLI) are well-established label-free analytical technologies used to determine biomolecular interaction rates ( k a , k d ) and equilibrium constants ( K D ). While assays historically rely on multi-cycle kinetics (MCK), this approach requires intermediate surface regeneration, risking sensor degradation and increasing reagent consumption. Single-cycle kinetics (SCK) avoids regeneration by sequentially injecting increasing analyte concentrations. However, implementing SCK workflows on biosensor platforms like the Octet ® R8 BLI instrument (Sartorius) remains a challenge due to the lack of built-in or online data analysis tools. To address this, we introduce SCKAnalyzer, a free, user-friendly web application designed for processing and fitting SCK datasets. SCKAnalyzer accepts column-based text files and native raw BLI data (.frd format) from Sartorius instruments, performing data pre-processing and non-linear fitting to a 1:1 interaction model. Additionally, it offers advanced simulation capabilities that allow variable association and dissociation durations across sequential injection steps, a feature absent in existing platforms such as Biacore™ Simul8. The performance of SCKAnalyzer was experimentally validated using a 3-step SCK method (SCK3) for DNA/RNA duplex formation on a Biacore T200, as well as 4-step (SCK4) and 5-step (SCK5) methods for DNA/DNA duplex formation on an Octet ® R8 BLI instrument. Binding parameters ( k a , k d , K D ) derived from SCKAnalyzer showed excellent agreement with values from established proprietary softwares such as Biacore T200 Evaluation Software v3.2.1 and BIAevaluation v4.1.1. SCKAnalyzer provides a practical alternative to MCK, reducing probe consumption and extending SCK utility across biosensor platforms. SCKAnalyzer is available at sck.iecb.u-bordeaux.fr (source code: github.com/synthaze/sckanalyzer ).

  • Structural and dynamic studies of TCTP protein : deciphering a complex interaction network involved in tumor reversion

    by Florian Malard

    Etude structurale et dynamique de la protéine TCTP : vers la caractérisation d’un réseau d’interaction complexe dans la réversion tumorale: TCTP est une petite protéine globulaire (20~kDa) qui interagit avec de nombreux partenaires et qui est impliquée dans diverses fonctions cellulaires et physiologiques, avec un rôle bien documenté dans la réversion tumorale qui est un phénomène rare et spontané où une cellule cancereuse perd tout ou partie de son phénotype malin et retrouve des caractéristiques associées aux cellules bénignes telles que la sensibilité à l'apoptose. Dans les cellules cancéreuses, TCTP inhibe la dégradation de MDM2, diminuant ainsi les niveaux de p53 et favorisant le maintien et la progression du cancer. TCTP contient également un motif BH3-like connu pour réguler les membres de la famille Bcl-2 et elle interagit directement avec Bcl-xL et Mcl-1 pour renforcer leurs propriétés anti-apoptotiques. Dans la structure TCTP, le motif BH3-like n'est pas facilement accessible pour une interaction avec un partenaire. Conformément à son importance dans le maintien de la tumeur, TCTP est une cible pharmacologique validée dans le traitement du cancer et fait l’objet d’essais cliniques en cours avec une molécule d'abord connue comme anti-depresseur, la sertraline. Cependant, on en sait peu sur la structure de TCTP en complexe avec ses partenaires, ce qui entrave le développement de médicaments et ne permet pas de comprendre comment TCTP peut s'adapter à une telle variété de partenaires. Ainsi, nous avons étudié le mécanisme moléculaire par lequel TCTP s'associe à des protéines et à des ligands en utilisant diverses méthodes biophysiques (RMN, SAXS, CD, SEC, DSF...). Nous avons démontré que la protéine TCTP se lie à Bcl-xL et à Mcl-1 dans le sillon de liaison des motifs BH3. Dans les complexes, la région BH3-like est engagée dans l'interface intermoléculaire et la structure centrale de TCTP est déstabilisée dans un état de globule fondu (molten-globule). Nous avons en outre montré que seule une forme mineure pré-existante de TCTP, à savoir TCTP*, est compétente pour les interactions avec les partenaires Bcl-xL et Mcl-1. Dans TCTP*, la région BH3-like est détachée du domaine structuré et elle est accessible aux protéines Bcl-xL/Mcl-1 tandis qu'on retrouve un état globule fondu dans la partie globulaire de TCTP*. Nous avons également collecté des données d'interaction préliminaires entre TCTP et la sertraline, des ARN, la protéine YB-1 se liant à l'ARN et le domaine N-terminal de MDM2. Enfin, nous avons caractérisé TCTP phosphorylé (pTCTP) au résidu S46 en utilisant la Plk-1 car cette modification a un impact sur les interactions et est un marqueur de l'aggressivité tumorale. En résumé, ces travaux ont établi la versatilité de TCTP en terme de structure et ont montré que cette versatilité est indispensable pour exercer ses fonctions cellulaires. En conséquence, ceci devrait être pris en compte dans les stratégies de développement de nouvelles molécules thérapeutiques ciblant TCTP.

  • Open Access

    Transcript‐Level Modulation of O ‐GlcNAc Transferase for Aging‐Related Neurodegenerative Diseases

    by Florian Malard

    The O ‐GlcNAc Transferase (OGT) is responsible for the addition of β‐ O ‐linked N‐acetyl‐D‐glucosamine ( O ‐GlcNAc) to serine and threonine residues, thereby regulating more than 8000 human proteins through O ‐GlcNAcylation. In the brain, reduced O ‐GlcNAc levels, which can arise from insufficient OGT activity, have been increasingly linked to aging‐related neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. While current strategies focus on restoring O ‐GlcNAc levels via O ‐GlcNAcase (OGA) inhibition, recent discoveries highlight transcript‐level regulation of OGT as a direct and promising therapeutic target. This concept article explores the role of intron detention and decoy exon‐mediated splicing repression in limiting OGT pre‐mRNA maturation and proposes the use of antisense oligonucleotides or selective splicing factor degraders to promote productive splicing and nuclear export of OGT mRNA. By enhancing OGT expression independently of O ‐GlcNAc feedback, these approaches aim to restore proteostasis and improve resilience to neurodegeneration, offering a novel therapeutic approach for aging‐related neurodegenerative diseases.


  • 1H, 13C and 15N backbone resonance assignment of the RNA binding motif 39 (RBM39) tandem RNA recognition motifs (RRM1−2)

    by Florian Malard, Léa Bouton, Sébastien Campagne

    The N-terminal tandem RNA Recognition Motifs (RRM1−2) of the splicing factor RNA Binding Motif 39 (RBM39) from Homo sapiens was expressed in E. coli with 13C and 15N labeling. A nearly complete assignment of backbone 1H, 15N, and 13C resonances was obtained, along with a secondary structure prediction based on the assigned chemical shifts. The predicted secondary structures of the RBM39 tandem RRM1−2 closely matched the published solution structures of the individual RBM39 RRM1 and RRM2, and also aligned well with the AlphaFold2 model of RBM39.


  • Open Access

    ASOG: AntiSens Oligonucleotides Generator

    by Jonah Kimi, Patricia Korczak, Brune Vialet, Eric Roubin, Philippe Barthélémy, Sébastien Campagne, Florian Malard

    Antisense oligonucleotides (ASOs) are used in both fundamental research and clinical applications to modulate gene expression by targeting the RNA transcript of specific genes. Historically, ASOs were designed manually, a time-consuming process that limited exhaustive searches through the ASO space. More recently, resources have been developed based on traditional or deep learning approaches to facilitate ASO design, each with its specific use cases and limitations. In this context, we propose an original and generalistic pipeline for ASO design, based on explicit criteria, original algorithms, and third-party software, encapsulated in a web application we named AntiSense Oligonucleotide Generator (ASOG). The ASOG pipeline requires only a target gene sequence as input, and it proceeds with ASO generation, predicts the structural properties of target subsequences, predicts splice site masking, detects off-target effects, and computes thermodynamic hybridization parameters, taking into account the most common RNA modifications. ASOG is designed to enable users to quickly navigate the ASO space, assisting them in making informed decisions. The ASOG webserver is available at https://asog.iecb.u-bordeaux.fr.

  • Open Access

    ASOG: AntiSense Oligonucleotide Generator

    by Jonah Kimi, Patricia Korczak, Brune Vialet, Eric Roubin, Philippe Barthélémy, Sébastien Campagne, Florian Malard

    Antisense oligonucleotides (ASOs) are used in both fundamental research and clinical applications to modulate gene expression by targeting the RNA transcript of specific genes. Historically, ASOs were designed manually, a time-consuming process that limited exhaustive searches through the ASO space. More recently, resources have been developed based on traditional or deep learning approaches to facilitate ASO design, each with their specific use cases and limitations. In this context, we propose an original and generalistic pipeline for ASO design, based on explicit criteria, original algorithms, and third-party software, encapsulated in a web application we named AntiSense Oligonucleotide Generator (ASOG). The ASOG pipeline requires only a target gene sequence as input, and it proceeds with ASO generation, predicts the structural properties of target subsequences, predicts splice site masking, detects off-target effects, and computes thermodynamic hybridization parameters, taking into account some of the most common RNA modifications. ASOG is designed to enable users to quickly navigate the ASO space, assisting them in making informed decisions. The ASOG webserver is available at asog.iecb.u-bordeaux.fr.


  • 1H, 13C and 15N backbone resonance assignment of the calcium-activated EndoU endoribonuclease

    by Florian Malard, Fedor V. Karginov, Sébastien Campagne

    The catalytic domain of the calcium-dependent endoribonuclease EndoU from Homo sapiens was expressed in E. coli with 13C and 15N labeling. A nearly complete assignment of backbone 1H, 15N, and 13C resonances was obtained, as well as a secondary structure prediction based on the assigned chemical shifts. The predicted secondary structures were almost identical to the published crystal structure of calcium-activated EndoU. This is the first NMR study of an eukaryotic member of the EndoU-like superfamily of ribonucleases.


  • Studying the O-GlcNAcome of human placentas using banked tissue samples

    by Sarai Luna, Florian Malard, Michaela Pereckas, Mayumi Aoki, Kazuhiro Aoki, Stephanie Olivier-Van Stichelen

    O-GlcNAcylation is a dynamic modulator of signaling pathways, equal in magnitude to the widely studied phosphorylation. With the rapid development of tools for its detection at the single protein level, the O-GlcNAc modification rapidly emerged as a novel diagnostic and therapeutic target in human diseases. Yet, mapping the human O-GlcNAcome in various tissues is essential for generating relevant biomarkers. In this study, we used human banked tissue as a sample source to identify O-GlcNAcylated protein targets relevant to human diseases. Using human term placentas, we propose (1) a method to clean frozen banked tissue of blood proteins; (2) an optimized protocol for the enrichment of O-GlcNAcylated proteins using immunoaffinity purification; and (3) a bioinformatic workflow to identify the most promising O-GlcNAc targets. As a proof-of-concept, we used 45 mg of banked placental samples from two pregnancies to generate intracellular protein extracts depleted of blood protein. Then, antibody-based O-GlcNAc enrichment on denatured samples yielded over 2000 unique HexNAc PSMs and 900 unique sites using 300 μg of protein lysate. Due to efficient sample cleanup, we also captured 82 HexNAc proteins with high placental expression. Finally, we provide a bioinformatic tool (CytOVS) to sort the HexNAc proteins based on their cellular localization and extract the most promising O-GlcNAc targets to explore further. To conclude, we provide a simple 3-step workflow to generate a manageable list of O-GlcNAc proteins from human tissue and improve our understanding of O-GlcNAcylation’s role in health and diseases.


  • Small molecules modulating RNA splicing: a review of targets and future perspectives

    by Léa Bouton, Agathe Ecoutin, Florian Malard, Sébastien Campagne

    In eukaryotic cells, RNA splicing is crucial for gene expression. Dysregulation of this process can result in incorrect mRNA processing, leading to aberrant gene expression patterns. Such abnormalities are implicated in many inherited diseases and cancers. Historically, antisense oligonucleotides, which bind to specific RNA targets, have been used to correct these splicing abnormalities. Despite their high specificity of action, these oligonucleotides have drawbacks, such as lack of oral bioavailability and the need for chemical modifications to enhance cellular uptake and stability. As a result, recent efforts focused on the development of small organic molecules that can correct abnormal RNA splicing event under disease conditions. This review discusses known and potential targets of these molecules, including RNA structures, trans-acting splicing factors, and the spliceosome – the macromolecular complex responsible for RNA splicing. We also rely on recent advances to discuss therapeutic applications of RNA-targeting small molecules in splicing correction. Overall, this review presents an update on strategies for RNA splicing modulation, emphasizing the therapeutic promise of small molecules.


  • Open Access

    Structural transitions in TCTP tumor protein upon binding to the anti-apoptotic protein family member Mcl-1

    by Florian Malard, Christina Sizun, Aurélien Thureau, Ludovic Carlier, Ewen Lescop